ストックスクリーナーアプリを入手
83.46
6.95%
5.42
前日終値:
$78.04
開ける：
$79.51
24時間の取引高:
311.24K
Relative Volume:
1.90
時価総額：
$649.92M
収益：
-
当期純損益:
$-4.98M
株価収益率:
-63.34
EPS:
-1.3177
ネットキャッシュフロー:
$-3.85M
1週間 パフォーマンス:
+1.63%
1か月 パフォーマンス:
+18.00%
6か月 パフォーマンス:
+197.97%
1年 パフォーマンス:
+103.02%
1日の値動き範囲:
$76.00
$84.58
1週間の範囲:
$75.11
$84.58
52週間の値動き範囲:
$23.18
$97.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
DRUG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
83.46 | 607.71M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-08 | 開始されました | BTIG Research | Buy |
| 2025-05-13 | 開始されました | TD Cowen | Buy |
| 2025-05-07 | 開始されました | Chardan Capital Markets | Buy |
| 2025-01-23 | 開始されました | Piper Sandler | Overweight |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Bright Minds Biosciences Inc (DRUG) 最新ニュース
Bright Minds Biosciences’ (DRUG) Buy Rating Reaffirmed at Chardan Capital - Defense World
Chardan Capital Reaffirms Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
HC Wainwright Has Negative Outlook for DRUG Q1 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Trading 4.2% HigherHere's Why - MarketBeat
H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target - Investing.com Nigeria
Bright Minds Biosciences (NASDAQ:DRUG) Given “Buy” Rating at HC Wainwright - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright - MarketBeat
Bright Minds Biosciences (DRUG) Expected to Announce Quarterly Earnings on Monday - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Rating Increased to Hold at Wall Street Zen - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Sees Large Volume Increase – Time to Buy? - Defense World
How Bright Minds Biosciences Inc. stock performs in high volatility marketsDividend Stability Analysis & Superior Trading Ideas - bollywoodhelpline.com
Bright Minds Biosciences (DRUG) Projected to Post Earnings on Monday - MarketBeat
DRUG: R&D-driven net loss rose to $12.2M; $82.9M cash secures 12+ months' runway amid ongoing clinical trials - TradingView — Track All Markets
Will Bright Minds Biosciences Inc. stock reach Wall Street targetsLayoff News & Low Drawdown Trading Strategies - Улправда
How institutional buying supports Bright Minds Biosciences Inc. stock2025 Market Sentiment & Stock Market Timing Techniques - Улправда
Why Bright Minds Biosciences Inc. stock is popular among millennials2025 Market Overview & Weekly High Return Stock Forecasts - Улправда
TD Cowen analyst highlights 10+ potential biotech catalysts for 2026 By Investing.com - Investing.com Canada
Will Bright Minds Biosciences Inc. stock deliver shareholder valueMarket Performance Summary & Risk Controlled Stock Pick Alerts - Улправда
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 5.4%Here's What Happened - MarketBeat
Bullish Divergence Spotted in Tulsyan NEC Limited MomentumDividend Yield Trends & Fast Growing Investment Plans - earlytimes.in
Bright Minds Biosciences Inc Stock Analysis and ForecastCurrency Fluctuation Impact & Free Tools to Monitor Market Corrections - earlytimes.in
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Reaches New 52-Week HighTime to Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 7.3%Here's Why - MarketBeat
Bright Minds Biosciences has standout year with epilepsy drug in Phase II trials - Proactive financial news
Bright Minds Biosciences (NASDAQ:DRUG) Hits New 1-Year HighTime to Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Sets New 52-Week HighStill a Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 10.3%Time to Buy? - MarketBeat
Walleye Capital LLC Cuts Stock Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
What drives Bright Minds Biosciences Inc stock priceEnergy Sector Updates & High Yield Trading Signals - earlytimes.in
Bright Minds Biosciences (NASDAQ:DRUG) Reaches New 1-Year HighHere's Why - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Cut to Hold at Zacks Research - Defense World
Why Bright Minds Biosciences Inc. stock attracts high net worth investorsPortfolio Growth Summary & Fast Gaining Stock Strategy Reports - Newser
Cantor Fitzgerald Analysts Lower Earnings Estimates for DRUG - MarketBeat
An Intrinsic Calculation For Bright Minds Biosciences Inc. (CSE:DRUG) Suggests It's 44% Undervalued - simplywall.st
DRUG FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World
(DRUG) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 7.2%Still a Buy? - MarketBeat
What technical signals suggest for Bright Minds Biosciences Inc. stockJuly 2025 Patterns & Reliable Volume Spike Alerts - Newser
Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why - MSN
Cantor Fitzgerald reiterates Overweight rating on Bright Minds Biosciences stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight rating on Bright Minds Biosciences stock - Investing.com Nigeria
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet - MSN
Brokerages Set Bright Minds Biosciences Inc. (NASDAQ:DRUG) Target Price at $81.00 - Defense World
Bright Minds Biosciences Inc (DRUG) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):